Lorenz Lehmann

19PUBLICATIONS
138CO-AUTHORS
Molecular targetsExercise physiologyPredictive and prognostic markersAutoimmunityCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (19)

|Sep 04, 2026
HDAC inhibition via suberoylanilide hydroxamic acid ameliorates doxorubicin-induced cardiotoxicity.

|Aug 18, 2026
MCL-1 inhibition triggers a largely reversible cardiac stress signature in a humanised mouse model.

|Jul 15, 2026
Exercise training for cardiovascular prevention in patients with cancer.

|Feb 07, 2026
The impact of acute coronary syndrome on long-term survival in cancer patients.

Daniel Finke, Markus B Heckmann, Jessica M Schug

|Jun 26, 2025
Immune checkpoint inhibitor-associated myocarditis: a novel risk score.

John R Power, Charles Dolladille, Benay Ozbay

|Jun 16, 2025
Feasibility Study for Long-Term Cardiotoxicity in Dose-Dense Treated Cancer Patients.

Markus B Heckmann, Julia Lehmann, Daniel Finke

Pageof 4

Frequent Collaborators

5 joint publications

Markus B Heckmann

5 joint publications

Joe-Elie Salem

4 joint publications

Stephane Ederhy

3 joint publications

Adrien Procureur